- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04084665
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
A Pilot Study to Examine Safety, Activity and Biomarkers in Participants With Hidradenitis Suppurativa Receiving a Previously Tested Subcutaneous Dose of Anti-IL-23 Monoclonal Antibody Guselkumab.
Hidradenitis Suppurativa (HS) is a severe, chronic debilitating disease with a variable and incomplete response to current treatments. Existing immunological studies have found dysregulation in the TH17:Treg axis with an increase in inflammatory mediators including TNFalpha, IL-17 IL-23 (amongst others) in lesional skin. Multiple cell typesincluding CD4+ cells, dendritic cells and macrophages infiltrate active lesions of HS and produce this major contribution from the Th17 axis.
One of the main barriers to the development of novel and effective treatments for HS is the lack of biomarker(s) of disease activity, as well as our incomplete understanding of the pathogenesis of this disease. Given the pronounced contribution of Th17 pathway (including interleukin-23) in the inflammation in HS, further investigation into the role of this axis in the pathogenicity of HS is essential. Guselkumab is a fully human interluekin-23 antagonist, FDA approved for the treatment of moderate to severe psoriasis in participants 18 years and over. Guselkumab is a novel potential therapy.
Study Overview
Detailed Description
Hidradenitis Suppurativa (HS) is a severe, chronic debilitating disease with a variable and incomplete response to current treatments. Existing immunological studies have found dysregulation in the TH17:Treg axis with an increase in inflammatory mediators including TNFalpha, IL-17 IL-23 (amongst others) in lesional skin. Multiple cell typesincluding CD4+ cells, dendritic cells and macrophages infiltrate active lesions of HS and produce this major contribution from the Th17 axis.
One of the main barriers to the development of novel and effective treatments for HS is the lack of biomarker(s) of disease activity, as well as our incomplete understanding of the pathogenesis of this disease. Markers such as C- Reactive Protein, IL-6, soluble IL-2 receptor, S100A8/9, lipocalin-2 and the neutrophil/lymphocyte rati7 have been proposed as potential biomarkers but lack high specificity and correlation with disease severity. Given the pronounced contribution of Th17 pathway (including interleukin-23) in the inflammation in HS, further investigation into the role of this axis in the pathogenicity of HS is essential. Guselkumab is a fully human interluekin-23 antagonist, FDA approved for the treatment of moderate to severe psoriasis in participants 18 years and over. Guselkumab is a novel potential therapy.
Study Type
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Rockefeller Unviersity
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have moderate to severe Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of medical history
- Have HS lesions present in at least 2 distinct anatomical areas
- Had an inadequate response to an adequate course of appropriate oral antibiotics for treatment of HS (or demonstrated intolerance to, or had contraindications to oral antibiotic treatment of their HS
- Have a total abscess and inflammatory nodule (AN) count greater than or equal to 3 at the screening and baseline visit
- Must agree with daily use (throughout the study of one of the following over the counter treatments to body areas affected with HS lesions: either soap and water, a topical antiseptic was containing chlorhexidine gluconate, triclosan or benzoyl peroxide, or a dilute bleach bath.
Exclusion Criteria:
- HIV Positive
- Active Hepatitis B or C Infection
- Pregnant or Breastfeeding
- No concurrent use of any systemic antibiotics/retinoids/immunosuppressants (require washout period of 5 half lives)
- Any medical, psychological or social condition that, in the opinion of the investigator would jeopardize the health or well being of the participant during any study procedures or integrity of the data
- Has a draining fistula count greater than 20 at baseline visit Any other active skin disease (bacterial fungal or viral infection) that could have interfered with the assessment of HS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Guselkumab 200mg q4 weekly
|
Guselkumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers at Week 12
Time Frame: Week 12 compared with baseline (Week 0).
|
Change in lesional tissue levels of IL-17A, IL-17C, IL-17F and IL-23, measured in pg/mL
|
Week 12 compared with baseline (Week 0).
|
Biomarkers at Week 24
Time Frame: Week 24 compared with baseline (Week 0).
|
Primary Outcomes would be the change in lesional tissue levels of IL-17A, IL-17C, IL-17F and IL-23 measured in pg/mL measured in pg/mL
|
Week 24 compared with baseline (Week 0).
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Week 0 to Week 24
|
Incidence of Grade 2/3 adverse events during the study
|
Week 0 to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Response at Week 12 (as measured by HiSCR)
Time Frame: Week 12 compared with Baseline
|
Clinical Response compared to baseline as assessed by the HiSCR (Hidradenitis Suppurativa Clinical Response) Defined as a greater than or equal to 50% reduction in inflammatory lesion count (abscesses plus inflammatory nodules), and no increase in abscesses or draining fistulas at Week 12 when compared with baseline
|
Week 12 compared with Baseline
|
Clinical Response at Week 12 (as measured by modified Sartorius Score)
Time Frame: Week 12 compared with Baseline
|
Clinical Response compared to baseline as assessed by the modified Sartorius Score as follows: Sum of separate scoring for each affected area using the data recorded as follows: a) 3 points per anatomical region involved; b) 6 points for each fistula and 1 point for each nodule or abscess; c) 1 point when the longest distance between two relevant lesions in each affected area is <5 cm; 3 points when it is 5-10 cm; and 9 points when it is >10 cm; d) 9 points when there is no clear separation of lesions from adjacent normal skin and 0 points when there is.
|
Week 12 compared with Baseline
|
Clinical Response at Week 12 (as measured by IHS4)
Time Frame: Week 12 compared with Baseline
|
Clinical Response compared to baseline as assessed by IHS4 (International Hidradenitis Suppurativa Severity Score) using the scoring system as follows: Total= (Number of nodules x1) + (Number of abscesses x2) + (Number of draining sinuses/fistulae x4)
|
Week 12 compared with Baseline
|
Clinical Response at Week 24 (as measured by HiSCR)
Time Frame: Week 24 compared with Baseline
|
Clinical Response compared to baseline as assessed by the HiSCR (Hidradenitis Suppurativa Clinical Response) Defined as a greater than or equal to 50% reduction in inflammatory lesion count (abscesses plus inflammatory nodules), and no increase in abscesses or draining fistulas at Week 24 when compared with baseline
|
Week 24 compared with Baseline
|
Clinical Response at Week 24 (as measured by modified Sartorius Score)
Time Frame: Week 24 compared with Baseline
|
Clinical Response compared to baseline as assessed by the modified Sartorius Score as follows: Sum of separate scoring for each affected area using the data recorded as follows: a) 3 points per anatomical region involved; b) 6 points for each fistula and 1 point for each nodule or abscess; c) 1 point when the longest distance between two relevant lesions in each affected area is <5 cm; 3 points when it is 5-10 cm; and 9 points when it is >10 cm; d) 9 points when there is no clear separation of lesions from adjacent normal skin and 0 points when there is.
|
Week 24 compared with Baseline
|
Clinical Response at Week 24 (as measured by IHS4)
Time Frame: Week 24 compared with Baseline
|
Clinical Response compared to baseline as assessed by IHS4 (International Hidradenitis Suppurativa Severity Score) using the scoring system as follows: Total= (Number of nodules x1) + (Number of abscesses x2) + (Number of draining sinuses/fistulae x4)
|
Week 24 compared with Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JFR-0992
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hidradenitis Suppurativa
-
Yale UniversityNot yet recruitingHidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | Hidradenitis Suppurativa \(HS\)United States
-
Boehringer IngelheimNot yet recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
-
Novartis PharmaceuticalsAvailableHidradenitis Suppurativa (HS)
-
AbbVie (prior sponsor, Abbott)CompletedHidradenitis Suppurativa (HS)
-
InflaRx GmbHQuintiles, Inc.CompletedHidradenitis Suppurativa (HS)United States, Bulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland
-
Erasmus Medical CenterNot yet recruitingHidradenitis Suppurativa, Acne Inversa
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan, Austria
-
Wake Forest University Health SciencesActive, not recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Clinical Trials on Guselkumab
-
Janssen Research & Development, LLCActive, not recruitingCrohn's DiseaseUnited States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Turkey, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, Hungary and more
-
Janssen Research & Development, LLCWithdrawn
-
University of California, San FranciscoJanssen Scientific Affairs, LLCRecruiting
-
University of California, San FranciscoJanssen Biotech, Inc.Recruiting
-
Janssen-Cilag Ltd.TerminatedPsoriasisItaly, Germany, Greece
-
University Medical Center GroningenJanssen-Cilag Ltd.CompletedHidradenitis SuppurativaNetherlands
-
Janssen-Cilag S.p.A.Completed
-
Janssen Research & Development, LLCCompletedHidradenitis SuppurativaUnited States, France, Canada, Germany, Netherlands, Denmark
-
Janssen Research & Development, LLCNo longer availableAdenomatous Polyposis Coli
-
Janssen Research & Development, LLCCompleted